BioLight Announces First IOPtiMate™ System Sale in Poland

TEL AVIV, Israel, December 1, 2014 /PRNewswire/ --

BioLight Life Sciences Investments Ltd.   (TASE: BOLT, OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate™ system to a medical center located in Poland following a successful product trial.

The sale of this first system in Poland is the result of the an intensive marketing campaign to leading physicians and medical centers mainly in Asia and also in other selected territories for the IOPtiMate™ system as part of the company's focus on markets with unmet needs for better solutions to treat glaucoma.

"We are pleased that this medical center selected the IOPtiMate™ system as its glaucoma surgery solution. This milestone conveys further confidence in our unique technology from the ophthalmology community and, along with our recent first sale in Hong Kong and our launch in China, demonstrates our ability to become a truly global player in this marketplace," said Suzana Nahum-Zilberberg, BioLight's chief executive officer.

The IOPtiMate™ system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.

About Glaucoma:  

Glaucoma, which created pressure within the eye causes damage to the optic nerve that may lead to full or partial blindness, is considered the second most common cause of blindness worldwide. According to estimates commonly accepted in the field, there are now about 67 million people worldwide that suffer from the disease. Glaucoma is usually a chronic disease requiring lifelong treatment, and based on assessments, the global market for drug therapy and surgery, is estimated at $4 billion annually.

About BioLight 

BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped around defined medical conditions - ophthalmology and cancer diagnostics. The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for dry-eye syndrome; and Eye-D^®, a controlled release drug-delivery insert platform. The cancer diagnostic activities include tests that are designated for bladder, cervical, multiple myeloma and other cancers.

Leading key investors, holding about 45% of BioLight's shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India's largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

For more information please visit the Company's website at http://www.bio-light.co.il.

CONTACTS:

BioLight
Itai Bar-Natan, CFO ([email protected] )
Tel: +972-73-2753400

SOURCE BioLight Life Sciences Investments Ltd

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED